Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance

About this update from Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance (TheNewswire)   Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support for the Global Congenital Heart Disease Alliance (“GCHDA”), a newly forming industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies.   GCHDA brings together industry partners, clinicians, researchers, regulators, investors, and patient communities to address the unique challenges facing innovators in congenital heart disease (CHD) - the most common birth defect in the world. Through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases, GCHDA aims to build a unified support ecosystem for a field that has long been fragmented.   The announcement comes on the heels of the World Heart Federation's World Heart Report 2026, which found that CHD now affects approximately 2% of live births globally and that the number of people living with CHD worldwide has grown to an estimated 16 million - up from 11.8 million three decades ago. The report also found that more than 90% of children in lower- and middle-income countries lack timely access to CHD care, underscoring the urgent need for the kind of cross-sector collaboration GCHDA is designed to enable.   "Congenital heart disease affects patients across every stage of life, from infancy through adulthood, and the technologies needed to diagnose and monitor these conditions require exactly the kind of collaborative ecosystem that GCHDA is working to build," said Joe Hostetter, Director of the CHD Program at Ventripoint Diagnostics. "With the growing CHD population and so many patients in underserved regions lacking access to timely care, we believe accurate, accessible imaging has to be part of the solution. Supporting GCHDA reflects our commitment to working alongside the broader CHD community to help close that gap."   Ventripoint's flagship platform, VMS+™, uses AI to transform standard 2D echocardiograms into highly accurate 3D models of all four heart chambers, bringing cMRI-level measure...

View stock analysis, news, and events for Ventripoint Diagnostics Ltd.